United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 14,440 Shares

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 14,440 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 9th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $474.65, for a total transaction of $10,679,625.00.
• On Monday, February 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.95, for a total value of $10,596,375.00.
• On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total transaction of $6,795,652.50.
• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total transaction of $3,659,197.50.
• On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $471.91, for a total value of $10,617,975.00.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total value of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $502.79, for a total value of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $514.35, for a total transaction of $11,572,875.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $473.43 on Wednesday. The firm’s 50 day moving average price is $484.23 and its two-hundred day moving average price is $443.45. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The stock has a market cap of $20.39 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 2.53 and a beta of 0.85.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research note on Wednesday, October 29th. Finally, Royal Bank Of Canada lifted their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

Institutional Trading of United Therapeutics

Several large investors have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in United Therapeutics during the third quarter valued at approximately $317,617,000. Norges Bank bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $293,418,000. Invesco Ltd. lifted its stake in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its stake in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.